Adverse experiences during short-term Sporal therapy occurred in about 7% of the patients. The most frequently reported adverse experiences were nausea (1.3%), abdominal pain (1.2%), headache (1%) and dyspepsia (0.7%).
During long-term therapy in patients, most of whom had major underlying pathology and multiple concomitant treatments, the incidence of adverse experiences was higher (16.2%). The most frequently reported adverse experiences were of gastrointestinal origin (6.1%), where nausea (2%) and epigastralgia (0.9%) were most commonly reported. A few cases of hypokalaemia have been observed during long-term therapy.